0001493152-26-017054
SEC filingAspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where shareholders approved five proposals including a reverse stock split, issuance of Series A Preferred Stock conversion shares, an ELOC-related common stock issuance, an increase in authorized common shares, and adjournment authority.
This shareholder vote represents a coordinated set of corporate actions designed to enhance Aspire Biopharma’s capital structure flexibility and regulatory compliance, particularly under Nasdaq Listing Rule 5635(d), which restricts equity issuances exceeding 19.99% of outstanding shares without prior shareholder approval. The approved reverse stock split—within a broad 1-for-5 to 1-for-500 range—suggests strategic preparation for potential delisting mitigation, future financing, or meeting minimum bid requirements, though the Board retains full discretion on timing and ratio. The dual approvals for Series A Preferred conversion shares and ELOC-related common stock issuance indicate active capital deployment plans tied to pre-existing agreements, both requiring explicit Nasdaq-compliant authorization due to their scale. The increase in authorized common stock from 490M to 700M shares removes a structural constraint on future equity-based transactions, including follow-on offerings or strategic partnerships. Finally, the adjournment authority reflects management’s anticipation of potential vote shortfalls—particularly evident in the Series A and ELOC proposals, where broker non-votes totaled over 1 million shares—underscoring reliance on discretionary voting by nominees. Collectively, these measures signal an inflection point toward operational scaling or financial restructuring, with material implications for share count, ownership dilution, and exchange listing stability.